Emerging pharmaceuticals that target metabolic and endocrine dysfunctions in polycystic ovary syndrome are transforming treatment paradigms. This article covers innovative drugs, including glucagon-like peptide 1 receptor agonists, sodium–glucose cotransporter 2 inhibitors, kisspeptin, neurokinin 3 receptor antagonists and artemisinins, exploring their mechanisms and potential to advance care for this disorder.
- Kaipeng Zhou
- Chen Lou
- Liangshan Mu